These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 3604266)
1. Pharmacokinetics and metabolism of mespirenone, a new aldosterone antagonist, in rat and cynomolgus monkey. Hildebrand M; Krause W; Kühne G; Hoyer GA Xenobiotica; 1987 May; 17(5):623-34. PubMed ID: 3604266 [TBL] [Abstract][Full Text] [Related]
2. Experimental studies on the endocrine side effects of new aldosterone antagonists. Nishino Y; Schröder H; el Etreby MF Arzneimittelforschung; 1988 Dec; 38(12):1800-5. PubMed ID: 3245852 [TBL] [Abstract][Full Text] [Related]
3. Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. Cook CS; Zhang L; Ames GB; Fischer J; Zhang J; Levin S Xenobiotica; 2003 Mar; 33(3):305-21. PubMed ID: 12637247 [TBL] [Abstract][Full Text] [Related]
4. Effect of a new mineralocorticoid antagonist mespirenone on aldosterone-induced hypertension. Opoku J; Kalimi M; Agarwal M; Qureshi D Am J Physiol; 1991 Feb; 260(2 Pt 1):E269-71. PubMed ID: 1996630 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of the novel anti-aldosterone compound mespirenone on adrenocortical steroidogenesis in vitro. Weindel K; Lewicka S; Vecsei P Arzneimittelforschung; 1991 Sep; 41(9):946-9. PubMed ID: 1796922 [TBL] [Abstract][Full Text] [Related]
7. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation. Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452 [TBL] [Abstract][Full Text] [Related]
8. Column liquid chromatography of the novel aldosterone antagonist, mespirenone, and its active metabolite in plasma. Hildebrand M; Schütt A J Chromatogr; 1987 Feb; 414(1):217-22. PubMed ID: 3571387 [No Abstract] [Full Text] [Related]
9. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists. Losert W; Bittler D; Buse M; Casals-Stenzel J; Haberey M; Laurent H; Nickisch K; Schillinger E; Wiechert R Arzneimittelforschung; 1986 Nov; 36(11):1583-600. PubMed ID: 3028435 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and biotransformation of methane sulphonanilides with anti-inflammatory activity in the rat and monkey--comparison with piroxicam. Krause W; Kühne G; Schillinger E Xenobiotica; 1983 May; 13(5):265-72. PubMed ID: 6636822 [TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes. Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451 [TBL] [Abstract][Full Text] [Related]
12. Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats. Kaukonen AM; Lennernäs H; Mannermaa JP J Pharm Pharmacol; 1998 Jun; 50(6):611-9. PubMed ID: 9680070 [TBL] [Abstract][Full Text] [Related]
13. Bioactivation of eptaloprost in animals and man. Hildebrand M Prostaglandins; 1993 Aug; 46(2):177-89. PubMed ID: 7692471 [TBL] [Abstract][Full Text] [Related]
14. New insights into the pharmacokinetics of spironolactone. Overdiek HW; Hermens WA; Merkus FW Clin Pharmacol Ther; 1985 Oct; 38(4):469-74. PubMed ID: 4042530 [TBL] [Abstract][Full Text] [Related]
15. Biotransformation of the antidepressant D,L-rolipram. II. Metabolite patterns in man, rat, rabbit, rhesus and cynomolgus monkey. Krause W; Kühne G Xenobiotica; 1993 Nov; 23(11):1277-88. PubMed ID: 8310711 [TBL] [Abstract][Full Text] [Related]
16. Biotransformation of BOF-4272, a sulfoxide-containing drug, in the cynomolgus monkey. Naito S; Nishimura M; Jin Y Eur J Drug Metab Pharmacokinet; 1999; 24(3):279-86. PubMed ID: 10716068 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye. Sjöquist B; Tajallaei S; Stjernschantz J Arzneimittelforschung; 1999 Mar; 49(3):225-33. PubMed ID: 10219466 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of the new aldosterone antagonist, spirorenone, in healthy volunteers after single and repeated daily doses. Krause W; Sack C; Seifert W Eur J Clin Pharmacol; 1983; 25(2):231-6. PubMed ID: 6628506 [TBL] [Abstract][Full Text] [Related]
20. Studies on the pharmacokinetics of ZK 96 480, a novel PGI2-mimetic, in rat and cynomolgus monkey. Hildebrand M Prostaglandins; 1986 Sep; 32(3):425-38. PubMed ID: 3538205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]